2,753
Views
7
CrossRef citations to date
0
Altmetric
Review Article

Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance

, &
Pages 73-90 | Received 16 Sep 2021, Accepted 15 Jan 2022, Published online: 20 Feb 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Toshiyuki Yamamoto. (2022) Skin Manifestation Induced by Immune Checkpoint Inhibitors. Clinical, Cosmetic and Investigational Dermatology 15, pages 829-841.
Read now

Articles from other publishers (6)

Fiorinda Muhaj, Padmavathi V. Karri, Wylie Moody, Alexandria Brown & Anisha B. Patel. (2023) Mucocutaneous adverse events to immune checkpoint inhibitors. Frontiers in Allergy 4.
Crossref
Ying Liu, Jiong Tang, Lin-Yuan Yu & Qian Jiang. (2023) Successful treatment of immune-related lichenoid dermatitis by Weiling decoction in a patient with non-small cell lung cancer: A case report and review of literature. EXPLORE.
Crossref
Tomoya Watanabe & Yukie Yamaguchi. (2023) Cutaneous manifestations associated with immune checkpoint inhibitors. Frontiers in Immunology 14.
Crossref
Michele DI COSOLA, Francesca SPIRITO, Piermichele SARACINO, Vito C. CAPONIO, Victor DIAZ-FLORES GARCIA, Gabriele MADONNA, Paolo ASCIERTO & Lorenzo LO MUZIO. (2023) Oral immune-related adverse events caused by immune checkpoint inhibitors: a retrospective study. Minerva Dental and Oral Science 71:6.
Crossref
Charlotte Emonet, Florence Tétart, Olivia Bauvin, Lucie Cellier, Philippe Courville, Claire Mignard, Raphaël Janela-Lapert, Alexis Lefebvre, Samy Lachkar, Diane Lechevalier, Laurence Lagarce, Priscille Carvalho & Billal Tedbirt. (2023) Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature. Journal of Immunotherapy 46:2, pages 59-63.
Crossref
Julianna Martel, Woo Cheal Cho, John S. Runge, Anisha B. Patel, Jean Tayar, Karin Woodman, Celyne Bueno Hume, Jonathan Curry & Meghan Heberton. (2022) Durvalumab-associated generalized morphea with overlapping vitiligo. JAAD Case Reports 30, pages 83-86.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.